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SUMMARY 
Quality of life is an essential component of the way Sjögren's syndrome should be 
evaluated, indicating that management of such patients as not a simple task one would 
think, but the life that the patient leads, and the quality of it must be engaged as a whole. 
Sjögren's syndrome is a chronic inflammatory autoimmune illness, slowly progressing 
and targeting the bodies exocrine glands. Ranging from xerophthalmia and xerostomia to 
more systemic and severe manifestations, Sjögren's syndrome may also co-exist with 
other diseases of autoimmune origin and also progress to more malignant scenarios. 
Somewhat subtle presentation leads to delays in all aspects, causing severe impairment of 
the life that this individual leads, both physically and mentally. Diagnosis remains one of 
the major difficulties, as it overlaps with other autoimmune diseases, making diagnosis 
usually a long and tedious process, burdening the patient and impairing their quality of 
life. The health related quality of life is a multifactorial assessment, and can be evaluated 
using different models to assess mental and physical well being, such as the Short-Form 
Health Survey questionnaire 36 (SF 36) and other patient centered questionnaires. The 
therapeutic management includes the separation into glandular and systemic 
manifestations and their respective treatment modalities. Symptomatic therapy dominates 
for the glandular manifestations, including replacement and stimulation of fluids, while 
various disease modifying drugs are used for these systemic or extraglandular 
manifestations. Impaired function is associated with reduced quality of life and symptoms 
such as pain, fatigue, and depression, as well as disease activity, illustrating the 
importance of optimal management of all aspects of the disease.  
Key words: Sjogren's syndrome, quality of life, xerophthalmia, xerostomia  
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1. INTRODUCTION 
 
Sjögren's syndrome has a great impact on the life of a person suffering from it, with tolls 
being taken throughout life on both the physical side and mental side, thus indicating how 
important the quality of life that these people lead is. A tremendous burden will be placed 
on these individuals if Sjögren's syndrome is looked at simply as a disease when the 
patient visits the physician, and not as a disease that persists throughout the patients life 
and influences the way it lived. The introduction of this paper is to highlight and display 
the key elements of Sjögren's syndrome and how it affects the life that these individuals 
lead. The main goal is to review literature focused on the more known facts about 
Sjögren syndrome in terms of disease etiology, epidemiology, predisposing and risk 
factors, signs and symptoms, diagnostic tests, and as well as the quality of life that is led 
when one has the illness and the treatment options and care that should be performed.  
Sjögren's syndrome is a chronic inflammatory autoimmune disorder. The syndrome may 
be primary or secondary, which is associated with connective tissue diseases such as 
rheumatoid arthritis or systemic sclerosis. The first to describe such a syndrome was 
Swedish ophthalmologist Henrik Sjögren, in the year 1933. The reason for this was 
because he noted a  connection between dry eyes, arthritis, and dry mouth. Assessing 
patients with chronic scenarios of these complaints, as well as fatigue, can lead to and be 
helpful for an early diagnosis. Sjögren's syndrome is characterized by lymphocytic 
infiltration and fibrosis of exocrine glands, especially of the salivary and lacrimal glands. 
This subsequently leads to a subtle range of signs and symptoms which ultimately results 
in a difficult and taxing way of life. This impaired quality of life is brought up mostly by 
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dry eyes, decreased salivation and dry mouth, vaginal dryness, dry cough, dysphagia, and 
if systemically involved, there may be manifestations through arthralgia, vasculitis, 
lymphadenopathy, lung, kidney and liver involvement, peripheral neuropathy, myositis, 
and fatigue. There is also an increased association with other autoimmune diseases and 
increased risk of lymphoma. This wide range of signs and symptoms that encompass this 
syndrome highlights the necessity for proper management. A multidisciplinary team is 
essential, including from ophthalmologists, rheumatologists, dental practitioners, nurses, 
and many others, to decrease the burden that people with this syndrome endure. As with 
other chronic diseases, permanent cures are uncertain, and the patient must learn to deal 
and ultimately live with such an illness.  
 
2. SJÖGREN'S SYNDROME 
 
2.1 Classification 
 
Sjögren's syndrome is an autoimmune disease highlighted by systemic and broad organ 
specific manifestations, of which the most dominant is decreased salivary and lacrimal 
gland function, keratoconjuctivitis sicca, parotid gland swelling, and xerostomia. As 
noted previously, primary Sjögren syndrome presents alone, while secondary presents 
itself in connection with other connective tissue diseases, such as rheumatoid arthritis, 
systemic lupus erythematosus, or scleroderma. Overall, Sjögren's syndrome can present 
as an isolated entity, limited to complaints related to decreased glandular function, or 
encompassing a more systemic presentation, both of which can be subtle and chronic. It 
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is precisely this complexity of presentations that has led to elaborate diagnostic and 
classification criteria.  
 
In 1993, the Preliminary European Classification criteria was published. This criteria was 
then reviewed and re-examined in 2002 by a joint European and American Committee. 
The final result of this revision was that it yielded the AECG-criteria (American and 
European Consensus Group classification), which introduced more clearly defined rules 
for classifying patients with primary or secondary Sjögren's syndrome and provided more 
accurate exclusion criteria (1). This criteria is not perfect, as it has its benefits and 
negative aspects, illustrating the difficulty in establishing a proper classification for 
diagnosis. One of the major differences that the AECG-criteria implemented was the 
obligatory need for serology or biopsy to confirm the diagnosis, therefore making it 
mandatory for an invasive procedure to be done to fulfill the criteria. Another factor that 
must be taken into account is that criteria does not have any influence on the prognosis of 
disease and that there are no prognostic factors included at all, which is something that 
makes the classification fall under criticism. The joint AECG-criteria is as follows: 
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Table 1 (C. Baldini et al. / Journal of Autoimmunity 39 (2012) 9e14) 
 
 
American-European Consensus Group Criteria. Revised international classification 
criteria for Sjögren’s syndrome. 
 
I. Ocular symptoms: a positive response to at least one of the following questions: 
 
1. Have you had daily, persistent, troublesome dry eyes for more than 3 months? 
2. Do you have a recurrent sensation of sand or gravel in the eyes? 
3. Do you use tear substitutes more than 3 times a day? 
 
II. Oral symptoms: a positive response to at least one of the following questions: 
 
1. Have you had a daily feeling of dry mouth for more than 3 months? 
2. Have you had recurrently or persistently swollen salivary glands as an adult? 
3. Do you frequently drink liquids to aid in swallowing dry food? 
 
III. Ocular signsdthat is, objective evidence of ocular involvement defined as a positive 
result for at least one of the following two tests: 
 
1. Schirmer’s I test, performed without anaesthesia (<5 mm in 5 min) 
2. Rose bengal score or other ocular dye score (>4 according to van Bijsterveld’s scoring 
system) 
 
IV. Histopathology: In minor salivary glands (obtained through normal-appearing 
mucosa) focal lymphocytic sialoadenitis, evaluated by an expert histopathologist, with a 
focus score >1, defined as a number of lymphocytic foci (which are adjacent to normal-
appearing mucous acini and contain more than 50 lymphocytes) per 4 mm2 of glandular 
tissue 
 
V. Salivary gland involvement: objective evidence of salivary gland involvement defined 
by a positive result for at least one of the following diagnostic tests: 
 
1. Unstimulated whole salivary flow (<1.5 ml in 15 min) 
2. Parotid sialography showing the presence of diffuse sialectasias (punctate, cavitary or 
destructive pattern), without evidence of obstruction in the major ducts 
3. Salivary scintigraphy showing delayed uptake, reduced concentration and/or delayed 
excretion of tracer 
 
VI. Autoantibodies: presence in the serum of the following autoantibodies: 
 
1. Antibodies to Ro(SSA) or La(SSB) antigens, or both 
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Revised rules for classification 
 
For primary SS 
 
In patients without any potentially associated disease, primary SS may be defined as 
follows: 
 
a. The presence of any 4 of the 6 items is indicative of primary SS, as long as either item 
IV (Histopathology) or VI (Serology) is positive 
b. The presence of any 3 of the 4 objective criteria items (that is, items III, IV, V, VI) 
c. The classification tree procedure represents a valid alternative method for 
classification, although it should be more 
properly used in clinical-epidemiological survey 
 
For secondary SS 
 
In patients with a potentially associated disease (for instance, another well defined 
connective tissue disease), the presence of item I or item II plus any 2 from among items 
III, IV, and V may be considered as indicative of secondary SS 
 
Exclusion criteria: 
 
Past head and neck radiation treatment 
Hepatitis C infection 
Acquired immunodeficiency disease (AIDS) 
Pre-existing lymphoma 
Sarcoidosis 
Graft-versus-host disease 
Use of anticholinergic drugs (since a time shorter than 4-fold the half life of the drug 
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An early and accurate diagnosis is of utmost importance to try and prevent and ultimately 
aim to prevent complications. It can also ensure treatment to be administered on time to 
aid in prevention. One of many complications that will be further touched upon is dental 
candidiasis. This occurs due to decreased salivation and oral dryness. If there is early 
restoration of salivary function then this can slow down and maybe even prevent the 
development of such an oral complication. Oral candidiasis is one of the more benign 
complications, early diagnosis and proper treatment can contribute to identifying possibly 
more dangerous systemic complications, such as lymphoma. One more factor that should 
be stressed is that the longer the disease remains undiagnosed, the longer a patients 
mental well being can suffer such as the anxiety of not knowing, as well as the their 
physical well being.  
 
2.2 Etiology 
 
Sjögren's syndrome is a progressive autoimmune disease, characterized by lymphocytic 
infiltration and a difficult pathogenesis that requires an involving immune cell production 
and activation, autoantibody production, and a predisposing genetic background. The 
etiology is unclear and unknown thus far, susceptibility to the disease can be ascribed to 
the connection and linkage between environmental, hormonal, and genetic influences (2). 
Of these factors, the constant stimulation of the immune system is said to be the most 
prominent variable, as noted through the production of various autoantibodies, 
particularly anti-Ro/SS-A and anti-La/SS-B. Further touching upon the genetics aspect, 
there is a familial association with other autoimmune diseases. It is documented that it is 
common for a patient with Sjögren's syndrome to have relatives with autoimmune 
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diseases, this association can reach up to 30% (3). For the development of autoimmune 
diseases, the major histocompatibility complex is the most well documented genetic risk 
factors. For Sjögren's syndrome, the most prominent haplotypes for the formation of anti-
Ro/La are DRB1 0301-DQB1 0201-DQA1 0501 (3). A consistent finding in patients with 
the syndrome is that there is B-cell activation, leading to infiltration of organs in the 
body. From an infectious perspective, trials show that certain viruses such as 
cytomegalovirus and hepatitis C can be postulated to cause Sjögren's syndrome (4). 
Whether these infectious agents truly cause the disease or simply mimic it through 
symptomatology is yet to be determined. Overall, the cause is yet to be determined, but it 
is deemed to be multifactorial, combining genetic, environmental, infectious, hormonal, 
and autoimmune factors.  
 
2.3 Epidemiology 
 
Sjögren's syndrome, having the perplexing clinical picture as described above, leads to a 
somewhat skewed number in terms of concluding how many people are actually affected. 
The criteria/classification listed above has led to some clarification, but ultimately many 
of the signs and symptoms are subtle and chronic, which leads to a partially subjective 
view and interpretation.  
 
Sjögren's syndrome is the second most common autoimmune rheumatic disease, with an 
estimated prevalence ranging between 0.1-4.2% of the population. Approximately 60% 
of Sjögren's syndrome patients have the disease secondary to an accompanying 
autoimmune disorder such as rheumatoid arthritis, systemic sclerosis, or SLE (5). It 
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mainly affects middle aged women, accumulating a female to male ratio of 9:1 (6). 
Average age occurrence is between 40-60 years of age. Due to its subtle and difficult 
symptomatology, affected individuals are often misdiagnosed and treated inadequately 
and not properly, leading to years of debilitating living standards. More than half of 
affected individuals remain undiagnosed, illustrating the difficulty in diagnosing 
Sjögren's syndrome.  
 
3. QUALITY OF LIFE 
 
Quality of life is a multidimensional structure, encompassing ones mental, physical, and 
social well being. As the population of world continues to rise in the category of age, it is 
therefore expected to not only assess and treat illnesses, but to evaluate the way of life 
thereafter. Adding to global factors such as morbidity and mortality, quality of life, and 
especially health related quality of life can provide great insight and can help build on the 
relationship between mental, medical, and social services.  
 
3.1 Importance  
 
This is an aspect that should not be overlooked for sufferers of chronic diseases. The 
overall burden can be one of important significance in the way these people lead their 
lives. This segment not only describes the importance of quality of life in Sjögren's 
syndrome, but also of other chronic diseases, highlighting the fact that this affects a great 
deal of people, and proper awareness and education about the topic should be stressed. 
Quality of life can be interpreted in a number of ways, whether it be through the social 
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circle one enjoys, the amount of riches one possesses, ones health, or various other 
variables, of which will be touched upon further throughout this paper. All these factors 
go hand in had with one another, and that is precisely why a broad view approach must 
be done, and not just viewing an illness as simply an illness. The importance of health 
related quality of life is because is very different compared to the disease the individual is 
suffering from. It cannot be deduced based on a clinical diagnosis but must be thoroughly 
evaluated. In a great deal of situations, patients often come to their physician looking to 
solve their symptoms and the way these symptoms are taking a toll on their everyday 
living. Patients can be bothered by their symptoms, worried about the future of their 
health, complain about not being able to perform daily activities, all of which can be 
addressed by the physician. Many time the physician treats the illness in this case, but 
this is in fact not why the patient came to seek help in the first place. Just as with the 
delays in diagnosing a disease such as Sjögren's syndrome, there are also delays in this 
entirely different aspect of the disease. It should thus be deduced that assessing and 
treating ones illness does not directly give knowledge about ones quality of life, which is 
why proper evaluations have been developed throughout the years.  
 
3.2 Quality of Life in Sjögren's Syndrome 
 
Factors that influence the quality of life in patients with Sjögren's syndrome can vary 
from symptoms that the patients suffers from, limitations in performing day-to-day 
activities, financial burden, emotional status, and social troubles. Signs and symptoms 
will be touched upon further in this paper, while this segment is to describe what actually 
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affects the quality of life in these individuals. Proper evaluation methods have been 
developed in the past, and these have given insight on the lifestyle of these patients. One 
major flaw in these methods of evaluation is that two separate individuals are attempting 
to quantify something. What the patient perceives as troubling or problematic is 
sometimes not felt with the same attitude from the physician, and vice versa. As a 
situation with multiple perspectives, different perspectives of the same objective situation 
can vary in interpretation. The effect of primary Sjögren's syndrome on a broad spectrum 
of quality of life including economic resources, work status, leisure activities and 
interpersonal relationships has not been well studied. Because primary Sjörgen's 
syndrome is predominantly diagnosed in peri-menopausal women, there is very limited 
data concerning the health status of younger women particularly those of child bearing 
age, as well as limited data concerning the health status of men with primary Sjögren's 
syndrome (7). There have been various studies trying to compare the physical, mental, 
and social aspects of Sjögren's syndrome to its fellow autoimmune diseases such a SLE 
and RA, with certain differences and similarities. Fatigue is one topic that is touched 
upon through various studies, as it can be detrimental for the patient. Alluding to the 
same conclusion, patients with Sjögren's syndrome have  substantially lowered quality of 
life based on questionnaires such as SF-36 described in the next segment of this paper. 
Sjögren's syndrome shares this similarity with its other autoimmune diseases such SLE 
and rheumatoid arthritis, the latter being even lower in terms of physical fatigue, while 
the former matching Sjögren's syndrome in other aspects of fatigue such as mental 
fatigue (8). It has also been postulated that there is also an inflammatory component 
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causing fatigue in Sjögren's syndrome, although data has been inconclusive showing this 
(9).  
 
Oral problems such as the lack of saliva predisposing to a somewhat immunodeficient 
state leads to certain oral infections and difficulties with swallowing. These pathological 
changes can be obvious, but if we delve deeper into such problems a conclusion can be 
reached with the problems that arise from difficult swallowing. What was once easy and 
effortless to swallow now becomes a burden for these people suffering from Sjögren's 
syndrome. This can be of great psychological concern, especially in the elderly with 
inadequate dentures, once again indicating that proper oral health is of great importance. 
It has also been documented that patients with Sjögren's syndrome also have an abnormal 
chemosensory perception, thus leading to difficulties with taste and smell. It might be 
anticipated that progressive exocrine gland damage with loss of secretions would affect 
the special senses of smell and taste, which contribute so much to daily functions and 
enjoyment of life (10). In conclusion, oral distress has proven to be a serious issue, with 
patients consistently scoring significantly lower than patients with low levels of oral 
distress in five of the SF-36 subscales, indicating that oral conditions have a marked 
impact on general quality of life (11).  
 
Continuous fatigue can be detrimental to ones health, and when combined with the other 
complaints of Sjögren's syndrome, can take a toll on ones mental being. Depression and 
anxiety can begin to manifest, and patients may begin to wonder why they have such a 
disease, what the consequences of their signs and symptoms will be, and will they ever be 
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able to lead normal lives. This psychological burden can be very negative when it come 
to the quality of life (12). Fortunately, cognitive impairment has not been noted in 
Sjögren's patients, although a healthy mental state may play a great role (13). One 
interesting study attempted to assess the defensive profile of primary Sjögren's syndrome  
patients and to investigate the independent associations of psychological distress and 
personality variables with health-related quality of life, concluding that there were 
difficulties for these patients, and that physicians should consider and address these 
issues as consequences of Sjögren's syndrome (14). The combination of fatigue and 
salivary abnormalities may even lead to sleep disturbances and excessive day time 
sleepiness, once again showing a very wide range of complications outside the usual 
'pathology' that first comes to mind.  
 
3.3 Assessing Quality of Life 
 
Sjögren's syndrome is very rarely a threat to ones life and it does not present in an acute 
fashion. As the disease is one of chronic manifestations, targeting the glands in primary 
Sjögren's syndrome and affecting the body in a systemic way in secondary Sjögren's, it is 
most certainly a threat to ones well being and lifestyle, and therefore ones quality of life. 
Health related quality of life (HRQOL) is a broad multidimensional concept that usually 
includes self-reported measures of physical and mental health (15). There are multiple 
ways of evaluating ones quality of life, many of them based on questionnaires. The 
Medical Outcomes Short-Form Health Survey questionnaire 36 (SF-36) is thus used as a 
model to evaluate and monitor the quality of life in patients in a clinical setting, and it has 
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shown to be a reliable and valid measure (16). The model of how this SF-36 
questionnaire is structured is displayed below (17): 
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SF-36 is just one of the many models that have been designed for measuring the quality 
of life, and more importantly the health related quality of life. Many assessments exist to 
only examine a single problem, while other assessments encompass various domains, 
such as the SF-36 measurement model.  
 
A very general approach used to assess population quality of life incorporated by the 
Centers for Disease Control and Prevention encompasses 4 general questions about ones 
health; Would you say that in general your health is excellent, very good, good, fair or 
poor, Now thinking about your physical health, which includes physical illness and 
injury, how many days during the past 30 days was your physical health not good, Now 
thinking about your mental health, which includes stress, depression, and problems with 
emotions, how many days during the past 30 days was your mental health not good, 
During the past 30 days, approximately how many days did poor physical or mental 
health keep you from doing your usual activities, such as self-care, work, or recreation 
(18).  
 
The Health Assessment Questionnaire (HAQ), is among the first patient reported 
outcome instruments designed to represent a model of patient-oriented outcome 
assessment. The HAQ is based on five patient-centered dimensions: disability, pain, 
medication effects, costs of care, and mortality (19).  
 
The World Health Organization Quality of Life Assessment-BREF (WHOQOL-BREF) 
questionnaire is yet another assessment used to evaluate the quality of life. Using such 
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broad evaluations such as this one, in combination with a selective assessment for a 
certain complaint such as fatigue, it can be properly evaluated whether ones quality of 
life is truly lowered, as shown through various studies (20).  
 
Fatigue is a frequent complaint and from both the mental and physical side can impair 
ones life. There are many evaluations that exist today to measure and assess fatigue, the 
majority of them being through questionnaires. The fatigue severity scale (FSS), the 
fatigue visual analogue scale (VAS-F), and the functional assessment of chronic illness 
therapy - fatigue (FACIT-F) are all ways of assessing fatigue individually, whether it be 
in relation to autoimmune diseases such as Sjögren's syndrome or not. One study used 
these measures to investigate fatigue change in pSS in a longitudinal study, and explore 
whether any clinical or laboratory variables at baseline, including serum cytokines, were 
associated with a change in fatigue scores over time (9).  
 
Oral health is another aspect of Sjögren's syndrome that requires attention as it requires 
extreme care so it does not impede the quality of life and even more importantly, so it 
does not progress to more severe complications. The Oral Health Impact Profile (OHIP-
49) can be used to assess oral quality, and in combination with other assessments of 
quality of health such as SF-36, can provide a great deal of information (21).  
 
Psychological issues play a large role in autoimmune diseases, the reasoning being that 
over time the patient endures dilemmas about how they perceive their illness. Whether 
they truly comprehend their disease or simply correlate their symptoms with their disease 
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are just a few of the issues that can become taxing over long periods of time. Depression 
and other mental illnesses may then show, further lowering the quality of life, and thus 
posing as a large problem in addition to already present physical complaints. The Patient 
Health Questionnaire (PHQ-9) and Hospital Anxiety and Depression Scale (HADS) are 
two assessments that have been used in the evaluation of the mental state of individuals 
with Sjögren's syndrome. These findings indicate that psychological factors are important 
correlates of health related quality of life in these disease groups and encourage the 
design of psycho-educational therapies targeting disease-related cognitions in pSS in an 
attempt to improve patient’s physical health related quality of life (12).  
 
The majority of individuals suffering from Sjögren's syndrome present with 
xerophthalmia, which then results in painful, erythematous, and itchy eyes. Associated 
with xerophthalmia is xerostomia, which is due to inadequate saliva. Insufficient saliva 
thus results in increased risk of cavities, taste disturbances, speech impeding, dysphagia 
and cough. The third classic symptom to complete this triad is tenderness and 
enlargement of the parotid glands. These are generally referred to the hallmark or classic 
signs and symptoms of Sjögren's syndrome and/or sicca syndrome. These signs and 
symptoms, although few, in addition with such systemic manifestations such as pain and 
fatigue, are the chief factors responsible for the decreased quality of life in patients with 
the disease. This segment contains a wide scope of signs and symptoms to evaluate, and 
this illustrates the few among many assessments necessary to complete such evaluations.  
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4. HEALTH RELATED QUALITY OF LIFE - COMPLICATIONS ARISING 
FROM SJÖGREN'S SYNDROME 
 
4.1 Oral Complications  
 
The oral distress that accompanies the disease can be very troubling for patients, not only 
to due to its constant effect, but also due its chronic one, thus resulting is serious 
implications on the health related quality of life. Studies have shown, and it has been 
proven that patients with Sjögren's syndrome have shown deteriorating salivary and 
lacrimal secretions. The rate of xerostomia increased from 41% at the initial diagnosis to 
84% 10 years after the diagnosis, again noting the negative fact that a person gone 
undiagnosed for a long period of time is prone to suffer a great deal more as opposed to 
being diagnosed early and treated appropriately (22). Saliva has a number of benefits, 
playing the role of lubrication of the oral cavity, as well as containing immunoglobulins, 
glycoproteins, and lysozymes to further aid in a protective fashion. The saliva that is 
produced helps limit the growth, production, and adherence of bacteria, thus also 
protecting against dental caries. Saliva is not only a protective factor against infection, 
but it also aids in lubrication of the oral cavity. Leading to a somewhat immunodeficient 
state, the oral cavity becomes prone to opportunistic infections such as Candida albicans. 
Oral dryness is not usually a painful complaint as it is a uncomfortable one, leading to 
many physicians to dismiss it as a quite common and irrelevant symptom unfortunately. 
An association with Candida organisms can result in angular cheilitis, which is indeed 
painful and further hampers the ability of the oral cavity (23). Other organisms such as 
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Streptococcus mutans and Lactobacillus are also reported with increased frequency. 
Prevalence of C.albicans is >68% in patients with Sjögren's syndrome compared to the 
prevalence in the normal population, which ranges between 23 to 68% (24). Decreased 
saliva production thus leads to increased irritability, erythematous swelling, 
inflammation, ulcer formation, and even in advanced cases, depapillation of the tongue. 
Difficulties in eating also ensues, as the food particles remain in the oral cavity due to 
inadequate clearance with saliva.  
 
Therefore, just as the most frequent complaint can be xerostomia, the patients may also 
complain of unpleasant taste, dysphagia, particularly while eating dry food, soreness and 
irritation. An article published by the University of Oslo in 2011 illustrates how the oral 
distress suffered by patients suffering from Sjögren's syndrome can severely impede their 
lives from day to day (25). The SF-36 was used to evaluate the health related quality of 
life and another survey was used to evaluate and measure the oral distress, the Oral 
Health Impact Profile 14. Compared to normal individuals not suffering from the disease, 
the patients with Sjögren's syndrome and oral distress scored significantly lower on the 
SF-36 survey. This indicates that there is a severe impact on the health related quality of 
life. This becomes an alarming fact, as oral conditions are one of the chief influences on 
the quality of life of these individuals. A greater deal of attention and focus must be 
directed on this issue with the aim of improving the quality of life for these patients.  
 
 
 
20 
 
4.2 Ocular Manifestations 
 
Xerostomia, xerophthalmia, and the symptoms related to these are the main complaints 
causing an impediment on the quality of life of these patients. Even more problematic is 
that they are quite common and thus can be dismissed quite readily. Another problem is 
that they are subjective complaints, and can thus be misinterpreted and mistaken for other 
general disorders such as anxiety or a sort of dermatitis.  
 
Dry eye is the most prominent ocular feature of Sjögren's syndrome, and it can 
encompass additional signs and symptoms such as a disturbing sensation, an itchy 
feeling, soreness, eye fatigue, photosensitivity, erythema, and decreased visual acuity. 
These features can even present themselves as the eye appears normal, further 
complicating efforts in diagnosis. Further complications in diagnosis is that although a 
hallmark of the disease is decreased tear production, it does not accurately correlate with 
ocular complaints and discomfort. It is therefore crucial when assessing the dry eyes of a 
patient, the aim should be to discover whether the objective signs are in proportion with 
the signs and symptoms of the patient.   
 
Further examination can reveal a decreased tear film and abnormal mucus component, 
leading to thick secretions and discharge. Complications can as well present themselves 
in the manner of conjuctivitis due to infection, opacification, ulceration of the cornea, and 
even perforation.  
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4.3 Female Sexual Function 
 
Unfortunately, diagnostic criteria do not specifically address vaginal dryness in patients 
with Sjögren's syndrome. Vaginal manifestations can result in severe discomfort for a 
woman, leading her to already known physical impairments and as well as mental 
suffering. Prevalence of dyspareunia and dryness in woman is high with primary 
Sjögren's syndrome. Surveys done in an article published very recently, in 2015, display 
dramatically lower scores in the areas such as sexual desire, lubrication, excitement and 
arousal, and orgasm. Compared to healthy controls, women with vaginal dryness reported 
sexual dissatisfaction, depressive symptoms, problems with their relationships and 
overall lower mental quality of life (26).  
 
Sexual function is considered to be vital to physical and mental health, and is associated 
with the satisfaction and general well being of an individual. Although the etiology of 
vaginal dryness is unknown, it is a well documented symptom, but the unfortunate matter 
is that it is viewed simply as that, a symptom. When assessing a patient with Sjögren's 
symptom, the complaint of vaginal dryness and dyspareunia is well noted, but the 
information of sexual function is not. Focusing solely on the number of times intercourse 
occurs or if there are vaginal sicca symptoms as opposed to the whole, broader concept of 
sexual function has a great effect on the mental and physical well being of the patient. If 
the primary complaint cannot be successfully dealt with, then physicians must have an 
open view to the cascade of complaints that may arise further down the line. 
Unfortunately, data on sexual function is scarce and limited in patients with primary 
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Sjögren's syndrome. The consequences of vaginal dryness are physical and psychological 
and must not be overlooked (27). This creates a negative cycle of decreased health related 
quality of life for the patient as well as a strained patient physician relationship. A great 
deal of patients do not communicate with their rheumatologist about this issue, either due 
to the subject never being brought up by the physician, the patient did not have a sexual 
relationship, or lubrication solved the issue (26). This miscommunication that can arise 
becomes a disturbing though when there is already enough difficulty in assessing signs 
and symptoms and the fact that more than half of the patients suffering from Sjögren's 
disease go unnoticed and undiagnosed for a large period of time. This begs the question 
as to why female sexual function is not specifically addressed in the diagnostic criteria.   
 
4.4 Mental Well Being 
 
Pain, fatigue, anxiety, depressive symptoms and somnolence in patients suffering from 
Sjögren's syndrome is quite well documented, but once again, a step further in the 
understanding is lacking. How these symptoms actually affect and impact the functional 
ability is generally not very well understood (28). Using another form of questionnaire, 
the Improved Health Assessment Questionnaire, it has been shown that patients with 
primary Sjögren's syndrome have a reduced capacity to perform a wide range of normal 
daily activities, thus heavily impeding their quality of life. The first study to take note of 
the significance of decreased functional status was the American College of 
Rheumatology in 2012, which noted a strong correlation between some, but not all of the 
clinical features of Sjögren's syndrome and decreased functional ability. Fatigue, dryness, 
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depression, anxiety, pain, and overall burden of disease showed a strong correlation, with 
fatigue displaying the largest influence (29). 
 
Fatigue somewhat goes hand in hand with functional ability, indicating that it is not an 
arbitrary attribute or a subjective complaint that should be falsely perceived. It is a 
debilitating and common symptom of Sjögren's syndrome, with approximately 70% or 
patients being affected. This is another symptom where self assessment comes into the 
picture and is needed to be performed to gather data and strategize a model for treatment. 
The pathogenesis of fatigue is an interesting one, encompassing physiological factors and 
as well as psychosocial ones. Other occurrences where fatigue plays a role in functional 
ability is post liver transplantation patients, patients with primary biliary cirrhosis, as well 
as many other chronic diseases and chronic treatment modalities, indicating that it is not a 
selective manifestation of Sjögren's syndrome.  
 
Another aspect that is worth mentioning is that inflammatory markers, such as C-reactive 
protein, seem to play a role in the fatigue that is experienced. This leads to the conclusion 
that perhaps treatment focusing on the articular systemic aspects of the disease can 
alleviate the fatigue and therefore help improve the health related quality of life (30). 
This evaluation and further knowledge on markers in the body could prove useful in the 
attempts of treating fatigue.  
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4.5 Pain 
 
Continuing on from our previous segment, fatigue and pain correlate in up to 85% of 
patients with primary Sjögren's syndrome. Muscle pain and joint pain can become a 
serious problem resulting in a cascade of negative effects both from a physical 
perspective as well as a psychological one.  
One heavy topic of conversation is that the pain that is accompanied by fatigue, 
psychological distress, and sleep disturbance is once again subjective and subject to a sort 
of bias perception. What the patient perceives as painful may be over exaggerated or 
thought of as more debilitating than it actually is, a distinct phenomenon which is 
characterized by feelings of helplessness, to ruminate, and excess imagination of 
cognitions and feelings toward the painful situation, in other words, catastrophizing (31). 
Many chronic diseases present with catastrophizing, such as cancer and other rheumatoid 
diseases, and this influences the intensity of chronic pain and can be useful in evaluating 
the patients' perception of pain. Pain catastrophizing can account for 36% of the variance 
in pain, 21% for variance in mood, and 27% variance in fatigue (32). As observed, this 
can be an alarming difference in the perception of the patients' symptoms, the steps taken 
in treatment, and the evaluation of their overall health. The catastrophizing of pain and its 
neural mechanisms raise an interesting potential target for therapy that could eventually 
influence the perception of pain.  
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4.6 Systemic Manifestations 
 
Adding further to the confusion and complication of establishing a diagnosis, many signs 
and symptoms of Sjögren's syndrome overlap closely with those of systemic 
erythematous lupus. Typically the result of chronic inflammation, these manifestations 
can affect almost the whole body, ranging from skin, arthralgia, myalgia, to more visceral 
components such as the kidney, lungs, endocrine, gastrointestinal, and nervous system.  
Athritis and arthralgia usually present in a symmetric distribution, and some patients even 
exhibit a pattern known as erosive arthritis. Development of some additional factor such 
as asymmetry and swelling could suggest another pathology that is underlying. In 
addition to myalgia, these are immense factors in the fatigue that these patients 
experience and the ongoing struggle that they suffer. Myalgia can be associated with 
fibromyalgia, and frequent analysis of electromyography, muscle enzymes and biopsies 
may be considered (33).  
 
Skin manifestations include alopecia, vasculitis, vitiligo, xerosis, and even lymphoma as 
a dire complication. Even the most simple thing like dry skin can cause severe 
discomfort. More than 10% of patients report a skin rash, while 18% report burning skin 
sensation in certain studies (5).  Lymphoproliferative disease is of particular importance 
in these patients because their risk of developing it is over 40 times the general 
population.  Clinically identifiable lymphoma occurs in approximately 5% of Sjögren's 
syndrome patients. Predictors of lymphoma do exist and require the monitoring of such 
patients. Predictors are of clinical and serological value. The majority of lymphomas are 
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of B-cell origin and are of low-intermediate grade malignancy, usually localizing in 
extranodal areas such as the gastrointestinal tract, thyroid gland, kidney, and lung.  
 
When it comes to pulmonary involvement, cough is usually the main presentation, a 
symptom of xerotrachea, while other complications include lymphocytic alveolitis, 
fibrosis, pneumonitis, and lymphoma.  
 
Pathology of the kidneys shows nephritis with glomerular sparing. Usually with 
tubulointerstitial involvement affecting the tubules, resulting in a cascade of problems 
such as renal tubular acidosis, hypercalcinuria, impaired concentration, and other tubular 
defects. Further grave complications can be development of nephrotic syndrome, 
hypertension, and ultimately renal insufficiency.  
 
In a recent study, it is shown that neurological involvement is one of the most common 
systemic manifestation, ranging from a presentation involving the peripheral or cranial 
nerves, and sometimes even the central nervous system (34). Peripheral neuropathies are 
the most common, and these tend to be primarily sensory.  
 
The involvement of the gastrointestinal tract is also profound, being able to affect the 
entire tract. Dysphagia and esophageal dysmotility are the most common presentations. 
Organ involvement also plays its role through mild hepatitis and pancreatitis, also adding 
to differential diagnosis of a wide range of other diseases.  
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5. MANAGEMENT 
 
Due to Sjögren's syndrome being a pathology of a wide range of signs and symptoms, 
treatment options can vary, ranging from pharmacology affecting individual and systemic 
manifestations, as well as non pharmacological treatment options targeting the mental 
health of the patient to alleviate the difficulty of this burden. Sjögren's syndrome can on a 
basic level either be a "benign" disease affecting the quality of life, or it can be a more 
systemic problem with more malignant aspects affecting morbidity and mortality more 
severely, thus requiring individualized therapy to adequately treat these different 
problems. Systemic manifestations overlap with other diseases, and to ease this thought, 
much of pharmacology does as well. An overall principle is that all most therapy should 
focus some efforts into preventing the dryness that occurs from this illness. How this is 
accomplished is through various fluids and drugs to try and keep the regions moist and 
lubricated, and as well as increase the production of natural lubricants. As an overall 
view, the majority of the drugs that were used in the treatment of autoimmune rheumatic 
diseases have also been administered to patients with Sjögren's syndrome, with the goal 
of alleviating symptoms such as the sicca symptoms described. Focusing on the aspect of 
prevention first and foremost is of utmost importance to ensure that the patient can lead 
as normal a life as possible, and then attention can shift to treating the various 
complication of Sjögren's syndrome.  
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5.1 Dry Eyes 
 
Possibly the most important aspect to focus therapy on, adequately managing ocular 
manifestations of Sjögren's syndrome is absolutely crucial for the patients well being and 
ultimately will influence the way they lead their lives (35). Methods that do not include 
pharmacology include measures such as avoiding prolonged straining of the eyes like 
extensive reading or staring at a screen for a long period of time, avoiding irritancies such 
as smoke, dust, and wind, and avoiding actual drugs that may influence the amount of 
fluid in the eye. These drugs include certain antidepressants, diuretics, cholinergic drugs, 
beta blockers, as well as antihistamines. If these measures cannot be adequately 
maintained or are not successful, then pharmacology must be opted for, resulting in 
attempts to replace fluid in the eyes and applications of certain topical drugs. 
Replacement of tear volume to limit the dryness in the eye is the priority, using artificial 
tears to do so. Emulsions that contain hyaluronate and hydroxyprpylmethyl-cellulose, 
hypotonic solutions that decrease osmolality seem to be the best options (3). Other 
options then to decrease dryness of he eyes include topical drugs, of which 
corticosteroids, cyclosporine A, and NSAID's prove to be useful. Emphasis for this was 
described earlier on throughout this paper, describing the large amount of complications 
of dry eyes that can greatly then hamper the lifestyle of people with Sjögren's syndrome. 
The limitations of topical drugs are that they are only permitted to be used for a short 
period of time, as prolonged use causes side effects that can worsen the condition, an 
example being decreased corneal sensitivity, predisposing to corneal irritation and 
ulceration to develop.  
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5.2 Dry Oral Cavity 
 
Just as with dry eyes, therapy can range from non pharmacological to pharmacological, 
with the aim being to reduce the complications associated with having a dry mouth. As 
mentioned previously, decreased salivation can lead to severe complications for the 
quality of life for a patient and the oral cavity. Most common of all is the development of 
caries, and also the increased incidence of oral infections. To limit this decreased 
salivation, fluoride has been used and has been shown to aid in this aspect, whether it be 
through fluoride containing toothpaste, specific gels, or certain rinses (36). Just as there 
are ocular tear substitutes, oral secretion substitutes for the purpose of lubrication also 
play a great role in preventing complications. Methods include the use of mouthwashes, 
gels, and other fluids such as drinking ordinary sugar free water to lead satisfying results. 
Chewing gum as a sort of mechanical stimulation has also been reported to yield some 
moderate success. As previously mentioned, adequate non pharmacological measures 
must also be attempted in order to preserve lubrication in the oral cavity and to enable the 
patient to live normally. Adequate hydration is a necessity, as well as avoiding irritants 
that can dry the mouth such as coffee and nicotine. If there are severe complaints and 
functions are impaired, then systemic drugs may also be used for therapeutic purposes. 
Cevimeline and pilocarpine are the two drugs of choice in most cases and as they are 
muscarinic receptor agonists, then side effects such as sweating, and increased urinary 
frequency must be looked out for (37). The patient must understand that accepting ones 
illness will result in a more positive outlook on the situation. In depth and obsessive care 
of the oral cavity must be undertaken, with frequent dental examination done, swift 
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treatment if something is noticed, and avoiding small mistakes that can be problematic, 
such as sleeping with dentures still in the mouth.  
 
5.3 Extraglandular Manifestations 
 
As stated previously, extraglandular manifestations may cause the patient a great deal of 
complications and problems in their lives, and one must know how to manage these 
properly. Systemic therapy can range from oldest drugs used in autoimmune therapy such 
as glucocorticoids, to infectious therapy such as antimalarial drugs, and finally to 
immunosuppressants and newer biological agents. A point worth noting is that with the 
use of all of these agents, especially the prolonged use, there is always a risk of severe 
side effects. Therefore a proper therapeutic plan must be executed, to ensure that the 
patient can live a fulfilling and rich life, despite the burden of their symptoms and the 
therapy they are being administered (38). A number of these drugs not only aid in the 
complications created by extraglandural manifestations, but also for the sicca symptoms 
that so frequently impair the quality of life of these patients. Drugs against malaria(most 
often hydroxychloroquine) have been shown to improve on arthromyalgia and fatigue, as 
well as improving on sicca symptoms through increasing salivary flow. With fatigue, 
patients must once again aim to live a normal life, with regular exercise being beneficial. 
and Antimalarials have also to an extent been shown to have antineoplastic properties, 
which is quite an interesting feature due to the fact that Sjögren's syndrome patients being 
at increased risk for developing lymphoma. Immunosuppressants seem to have a 
straightforward role in the treatment of Sjögren's syndrome, being used accordingly for 
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the specific organ involvement. More studies are necessary to form an adequate 
conclusion, as agents such as ciclosporin A, methotrexate, azathioprine are all used but 
with low amount of evidence to support.  
 
As treatment and diagnosis models slowly move into a molecular field, then biological 
agents logically become a field worthy of exploration. Although the true causes of 
Sjögren's syndrome are not known, thus rendering biological agents limited in a way, 
they still prove to be extremely beneficial and efforts are being directed at further 
research. According to a recent report published in 2012 (39),  there are no biological 
agents approved for the treatment of primary Sjögren's syndrome, although there are 
studies describing the potential of these drugs in future treatment models.  
 
The relationship between serum pro-inflammatory cytokines and a low quality of life is a 
strong one, indicating that there is still a great amount options in therapy to be explored. 
One such topic that has been touched upon in the effect of rituximab. Rituximab (anti 
CD20) infusions without corticosteroid therapy produced meaningful improvements in 
health related quality of life (40).  
 
6. CONCLUSION 
 
In conclusion, Sjögren's syndrome not only encompasses the well known signs and 
symptoms, but also factors in the quality of life that these individuals, signifying the 
absolute importance of addressing the patient as a whole and attempting to improve their 
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lives. The quality of life is an essential component of diagnostics and prognosis of people 
suffering with this illness. Through standard diagnostic and therapeutic methods for not 
only Sjögren's, but also many other chronic autoimmune diseases, the introduction of 
adequate support should be a priority. The need for constant evaluation and monitoring is 
a must, as nothing can be solved from little attempts, especially when dealing with 
chronic conditions. Although methods for assessment, diagnosis and treatment have 
improved throughout the years, there is still a long way to go. Diagnostic criteria and 
classifications still lack in certain aspects, and failure to properly identify a true cause of 
Sjögren's syndrome gives us a scope of treatments that are still not used to their complete 
function. Education is essential and the awareness to properly recognize early signs and 
symptoms is absolutely a must for the well being of the patient. As one of the more 
common autoimmune rheumatic diseases, it is a positive observation that further research 
and interest is being undertaken in an effort to fully understand this multifactorial disease. 
Despite improvement and progress in treatment, treatment will continue to be 
symptomatic and empirical unless a true etiology is discovered. As focus shifts on a 
molecular and genetic levels, improvements continue to be made through diagnostics 
such as salivary proteomics, systemic biology and genomics, there is some promise in 
unraveling the pathophysiology of Sjögren's syndrome. This will hopefully provide us 
with a more concentrated view into the underlying mechanisms which could give clues 
for intervention therapies with biological agents. Without a cure for Sjögren's syndrome, 
individuals must learn to live with it, and as illustrated above, this can be a difficult task. 
With a vast amount of problems complicating their lives, patients must accept and live 
with this burden. With the help of their families in both a physical and mental sense, 
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hope, and physicians, individuals can readjust their lives without allowing the disease to 
hinder them. Sjögren's syndrome is an incredibly complex one, and we must understand 
that individuals with it will suffer, indicating that more focus must be placed on 
recognizing these people and helping them in the best possible way. Through various 
articles and papers that have been published, it is recognized that there is a need for 
continuous aid through psychiatric and psychological support, both through diagnostics 
and through therapeutic models, as well as a need for a continuous evaluations of quality 
of life to ultimately improve all aspects of the lives of patients with Sjögren's syndrome.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
34 
 
ACKNOWLEDGEMENTS 
 
 
Foremost, I would like to express my sincere gratitude to my mentor Prof. Markeljević, 
MD, PhD, for the inspiration to pursue my study of rheumatology. Her expertise, 
motivation, guidance and teaching inspired me to pursue the topic of this thesis.  
 
Besides my mentor, I would like to thank the rest of my thesis committee: Assistant Miro 
Kalauz, MD, PhD, and Prof. Jadranka Sertić, MD, PhD.  
 
Last, but not least, I would like to thank my family for the support they provided me with 
throughout my entire life.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
REFERENCES 
 
 
1. Chiara Baldini, Rosaria Talarico, Athanasios G. Tzioufas, Stefano Bombardieri. 
Classification criteria for Sjögren’s syndrome: A critical review. Journal of 
Autoimmunity 2012; 30;39(1-2):9-14. 
 
 
2. Peri Y, Agmon-Levin N, Theodor E, Shoenfeld Y. Sjögren’s syndrome, the old and the 
new. Best Practice & Research Clinical Rheumatology 2012; 26:105–117. 
 
 
3. Tincani et al. Novel aspects of Sjögren’s syndrome in 2012. BioMed Central Medicine 
2013; 11:93. 
 
 
4. K Bayetto, RM Logan. Sjögren’s syndrome: a review of aetiology, pathogenesis, 
diagnosis and management. Australian Dental Journal 2010; 55 Suppl 1:39-47. 
 
 
5. Stuart S. Kassan, MD; Haralampos M. Moutsopoulos, MD, FRCP(Edin). Clinical 
Manifestations and Early Diagnosis of Sjögren's Syndrome. Archives of Internal 
Medicine 2004; 164:1275-1284. 
 
 
6. Catanzaro J, Dinkel S. Sjögren's Syndrome: The Hidden Disease. Medsurg Nursing 
2014; 23(4):219-23. 
 
 
7. Barbara Segal, Simon J Bowman, Philip C Fox, Frederick B Vivino, Nandita 
Murukutla, Jeff Brodscholl, Sarika Ogale and Lachy McLean. Primary Sjögren's 
Syndrome: health experiences and predictors of health quality among patients in the 
United States. Health and Quality of Life Outcomes 2009; 7: 46. 
 
 
8. S.J.Bowman, D.A. Booth, R.G. Platts, and UK Sjogren's interest group. Measurement 
of fatigue and discomfort in Sjögren's syndrome using a new questionnaire tool 2004; 
43(6):758-64. 
 
 
9. Karstein Haldorsen, Ingvar Bjelland, Anne Isine Bolstad, Roland Jonsson, and Johan 
Gorgas Brun. A five-year prospective study of fatigue in primary Sjögren’s syndrome. 
Arthritis Research & Therapy 2011; 13(5): R167. 
 
 
36 
 
10. Usama F. Kamel1, Peter Maddison and Rhiannon Whitaker. Impact of primary 
Sjögren’s syndrome on smell and taste: effect on quality of life. Rheumatology 2009; 48 
(12): 1512-1514. 
 
 
11. Enger TB, et al. Oral distress in primary Sjögren's syndrome: implications for health-
related quality of life. European Journal of Oral Sciences 2011; 119: 474–480. 
 
 
12. Konstantinos Kotsis, Paraskevi V. Voulgari, Niki Tsifetaki, Alexandros A. Drosos, 
André F. Carvalho, Thomas Hyphantis. Illness perceptions and psychological distress 
associated with physical health-related quality of life in primary Sjögren’s syndrome 
compared to systemic lupus erythematosus and rheumatoid arthritis. Rheumatology 
International 2014; Volume 34, Issue 12 , pp 1671-1681. 
 
 
13. Epstein LC, et al. Characterization of cognitive dysfunction in Sjögren's syndrome 
patients. Clinical Rheumatology 2014; 33:4 pg 511-21. 
 
 
14. Hyphantis T, et al. Clin Exp Rheumatol. The psychological defensive profile of 
primary Sjögren's syndrome patients and its relationship to health-related quality of life. 
Clinical & Experimental Rheumatology 2011; 29(3):485-93. 
 
 
15. http://www.cdc.gov/hrqol/ 
 
 
16. Garrat A M, Ruta D A, Abdalla M I, et al. The SF-36 Health Survey Questionnaire: 
an outcome measure suitable for routine use within the NHS. British Medical Journal 
1993; 306: 1440-1444. 
 
 
17. http://www.sf-36.org/tools/sf36.shtml 
 
 
18. http://www.cdc.gov/hrqol/methods.htm 
 
 
19. B. Bruce, J.F. Fries. The Health Assessment Questionnaire (HAQ). Clinical & 
Experimental Rheumatology 2005; 23 (Suppl. 39):S14-S18. 
 
 
 
 
37 
 
20. Inal V, et al. Evaluation of quality of life in relation to anxiety and depression in 
primary Sjögren's syndrome. Modern Rheumatology 2010; 20:588–597. 
 
 
21. López-Jornet P, et al. Quality of life in patients with Sjögren's syndrome and sicca 
complex. Journal of Oral Rehabilitation. 2008; 35; 875–881. 
 
 
22. Skopouli F, Dafni U, Ioannidis J, Moutsopoulos H. Clinical evolution, and morbidity 
and mortality of primary Sjögren’s syndrome. Seminars in Arthritis and Rheumatism 
2000; 29:296–304. 
 
 
23. Anaya JM, Talal N. Sjögren’s syndrome. In: Kassirer JP, Greene HL, eds. Current 
Therapy in Adult Medicine. 4th ed. Baltimore, Md: Mosby 1997; 1291-1298. 
 
 
24. Radfar L, Shea Y, Fisher S, et al. Fungal load and candidiasis in Sjögren’s syndrome. 
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, Endodontology 2003; 
96:283–287. 
 
 
25. Enger TB, Palm Ø, Garen T, Sandvik L, Jensen JL. Oral distress in primary Sjögren's 
syndrome: implications for health-related quality of life. European Journal of Oral 
Sciences 2011; 119(6):474-80.  
 
 
26. Jolien F. van Nimwegen, Suzanne Arends, Greetje S. van Zuiden, Arjan Vissink, 
Frans G. M. Kroese and Hendrika Bootsma. The impact of primary Sjögren’s syndrome 
on female sexual function. Arthritis & rheumatology 2014; Vol. 66, p. S1113-S1113. 
 
 
27. Fabre LF, Smith LC. The effect of major depression on sexual function in women. 
The Journal of Sexual Medicine 2012; 9:231_9. 
 
 
28. Ng WF, Bowman SJ. Primary Sjögren’s syndrome: too dry and too tired. 
Rheumatology (Oxford) 2010; 49:844–53. 
 
 
29. Katie L. Hacket, Julia L. Newton, James Frith, Chris Elliott, Dennis Lendrem, 
Heather Foggo, Suzanne Edgar, Sheryl Mitchell, and Wan-Fai NG. Impaired Functional 
Status in Primary Sjögren’s Syndrome. Arthritis Care & Research 2012; Volume 64, 
Issue 11, pages 1760–1764. 
 
 
38 
 
30. Tensing EK, Solovieva SA, Tervahartiala T, Nordström DC, Laine M, Niissalo S, 
Konttinen YT. Fatigue and health profile in sicca syndrome of Sjögren's and non-
Sjögren's syndrome origin. Clinical & Experimental Rheumatology 2001; 19(3):313-6. 
 
 
31. Lawrence Leung. Pain Catastrophizing: An Updated Review. Indian Journal of 
Psychological Medicine 2012; 34(3): 204–217.  
 
 
32. BM Segal, B Pogatchnik, N Rhodus, K Moser Sivils, G McElvain, CA Solid. Pain in 
primary Sjögren’s syndrome: the role of catastrophizing and negative illness perceptions. 
Scandinavian Journal of Rheumatology 2014; 43:234–241. 
 
 
33. Robert I Fox. Sjögren’s syndrome. Lancet 2005; 366(9482):321-31.  
 
 
34. Gemignani F, Marbini A, Pavesi G, et al. Peripheral neuropathy associated with 
primary Sjögren’s syndrome. Journal of Neurology, Neurosurgery, and Psychiatry 1994; 
57:983-986. 
 
 
35. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. 
Treatment of Sjögren’s syndrome-associated dry eye an evidence-based review. 
Ophthalmology 2011; 118:1242–1252. 
 
 
36. Clio P Mavragani, Niki M Moutsopoulos and Haralampos M Moutsopoulos. The 
management of Sjögren’s syndrome. Nature Reviews Rheumatology 2 2006; 252-261. 
 
 
37. Akpek EK, Lindsley KB, Adyanthaya RS, Swamy R, Baer AN, McDonnell PJ. 
Treatment of Sjögren’s syndrome-associated dry eye an evidence-based review. 
Ophthalmology 2011; 118:1242–1252. 
 
 
38. Rihl M, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with 
hydroxychloroquine in patients with Sjögren’s syndrome. Rheumatology (Oxford) 2009; 
48:796–799. 
 
 
39. http://www.biomedcentral.com/1741-7015/11/93 
 
 
39 
 
40. Devauchelle-Pensec V, et al. Effects of rituximab therapy on quality of life in patients 
with primary Sjögren's syndrome. Clinical & Experimental Rheumatology 2011; 29(1):6-
12. 
 
41. Hyphantis T, et al. The psychological defensive profile of primary Sjögren's 
syndrome patients and its relationship to health-related quality of life. Clinical & 
Experimental Rheumatology 2011; 29:3 pg 485-93. 
 
 
42. Vissink A, et al. Current and future challenges in primary Sjögren's syndrome. 
Current Pharmaceutical Biotechnology 2012; Volume 13, Number 10, pp. 2026-
2045(20). 
 
 
45. Usmani ZA, et al. Sleep disordered breathing in patients with primary Sjögren's 
syndrome: a group controlled study. SleepMed 2012; 13:8 pg 1066-70. 
 
 
46. Turner MD. Salivary gland disease in Sjögren's syndrome: sialoadenitis to 
lymphoma, review article. Oral & Maxillofacial Surgery Clinics of North America 2014; 
26(1):75-81. 
 
 
47. Eur J. Oral distress in primary Sjögren's syndrome: implications for health-related 
quality of life. International Journal of Oral Science 2011; 119: 474–480. 2011. 
 
 
 
 
 
 
 
 
 
 
. 
 
 
 
 
 
 
 
40 
 
BIOGRAPHY 
 
I was born on the 22nd of May, 1992, in Toronto, Canada. Currently I live in 
Zagreb, Croatia, attending the University of Zagreb, School of Medicine. As a child I 
completed my elementary education at Nativity of Our Lord Catholic School in 
Etobicoke, Toronto. My high school education was completed also in Etobicoke, 
Toronto, at Michael Power St. Joseph high school.  In the academic year of 2009/2010, I 
enrolled at the University of Zagreb, School of Medicine. In addition to my native 
language of English, I am fluent in Croatian and also excellent in French.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
41 
 
Curriculum Vitae 
 
 
PERSONAL 
INFORMATION 
Vicko Tabain 
 
 Heinzelova 30, 10 000 Zagreb (Croatia) 
+385 91 182 7495 
tvicko@gmail.com 
 
 
EDUCATION AND 
TRAINING  
 
 
 
 
PERSONAL STATEMENT Interested in working in the field of Internal Medicine, more specifically in the 
department of Rheumatology. Topics that peak my interest include autoimmune 
diseases and other areas of Internal Medicine such as Pulmonology, Immunology, 
Endocrinology, and Nephrology. Further interests include applying myself in 
research and publications. I believe to be fully capable based on my education 
and training, as well as based on great ambition to succeed. 
2009–2015 Degree of Doctor of Medicine  
University of Zagreb, School of Medicine, Zagreb (Croatia) 
2015 Medical Elective  
Princess Marina Hospital, Gaborone, Botswana, Gaborone (Botswana) 
▪ 4 week medical elective at the departments of Internal Medicine and Infectious 
Diseases 
2015 Medical School Graduation Thesis  
University of Zagreb, School of Medicine, Zagreb (Croatia) 
▪ Graduate thesis paper 
▪ "Quality of Life in Sjögren Syndrome patients" 
▪ Under the mentorship of Prof. Jasenka Markeljevic MD, PhD 
2015–Present Volunteer  
University Hospital Centre Zagreb, Zagreb (Croatia) 
▪ Volunteer at the plastic surgery ward 
42 
 
 
 
 
 
 
 
 
ADDITIONAL 
INFORMATION  
 
2012 Observership  
Health Centre Korcula, Korcula (Croatia) 
▪ Spent 1 month observing at a family practice, honing history taking and practical 
skills 
2011–2012 Demonstrator  
University of Zagreb, School of Medicine, Croatia 
▪ Teaching assistant for the Anatomy course 
2006–2009 "Michael Power/St. Joseph" Catholic Secondary School, Toronto 
(Canada) 
 
▪ Majority of Grade 12 University credits taken are in Science and Mathematics 
▪ Finished the 4 year required program (with more than 30 credits) in 3 years 
 
1996–2006 “Nativity of Our Lord” Catholic Elementary School, Toronto (Canada)   
▪ Grades JK to 4 attended the English Program 
▪ Grades 5 to 8 attended the French Immersion Program (50% of subjects taught 
in French) 
1996–2008 TCDSB and Dufferin-Peel Catholic School Board, Toronto (Canada)   
▪ International Languages Program 
▪ Completed the 12 year (elementary through high school) Croatian Language 
Program  
 
Mother tongue(s) English, Croatian 
  
Other language(s) UNDERSTANDING SPEAKING WRITING 
Listening Reading 
Spoken 
interaction 
Spoken 
production  
French  
Conferences ▪ 9th International Society for Applied Biological Sciences (ISABS) Conference on 
43 
 
 
 
 
 
 
Forensic, Anthropologic Genetics and Mayo Clinic Lectures in Individualized 
Medicine, 2015 
 
Presentations ▪ 9th International Society for Applied Biological Sciences (ISABS) Conference  
▪ Poster presentation in Molecular Diagnostics: Current Technology and 
Applications "GeneXpert MTB/RIF Role in the Absence of a Functional Lab" 
 
Certifications ▪ ECFMG Certificate, USA, 2013  
▪ Completed and passed USMLE Step 1 
 
Memberships ▪ School of Medicine, University of Zagreb 
▪ Member of the student council 2009-2011 
